Product Development
25+ years across monoclonal antibodies, biosimilars, and biologics in underserved high-need indications, from characterization through development execution.
About Us
Built around clarity, disciplined execution, and broader biologics access.
Inspired by clarity, precision, and elevation.
Named after the Gokyo region in the Himalayas, GokyoBio embodies disciplined execution and clarity of purpose, applying a focused, high-performance approach to complex biologics development.
Our Vision
To expand global access to life-saving, high-quality biologics while creating sustainable value for patients, partners, and healthcare systems.
Our Mission
To build an efficient biologics development platform and pipeline that accelerates timelines, enables scalable execution, and broadens access to high-quality therapies across immunology and underserved high-need indications.
Leadership & Strategic Ecosystem
We are supported by experts across biologics development, manufacturing, and regulatory execution.
Global Manufacturing
Proven success building global development and manufacturing networks from early development through commercial readiness.
Regulatory Strategy
Experienced in IND, BLA, and NDA-enabling strategy, with the rigor needed to support approval-ready biologics and global regulatory planning.
Leadership
Built on proven expertise across CMC development, scale-up, manufacturing strategy, and partnership building.
GokyoBio is led by experienced biotech leaders and advisors, with a growing leadership team supporting disciplined execution, strategic collaboration, and a scalable business model.
Founder, President and CEO
Kumar Dhanasekharan, Ph.D.
Established biologics development leader with 25+ years of experience across Genzyme-Sanofi,
Cook Pharmica, Amicus, SwanBio, Renovacor, and Voyager Therapeutics, with a passion to advance
broader access to high-quality biologics.
Medical and Regulatory Advisor
Andrew E. Mulberg, M.D., FAAP, CPI
Medical and regulatory advisor bringing global regulatory experience across J&J, FDA,
Amicus Therapeutics, and Neurogene in biologics and rare diseases.
General Counsel and Fractional CFO
Michael Alexander, J.D., Ph.D.
General counsel and fractional CFO bringing 30+ years of pharmaceutical and biotech experience
across corporate, R&D, intellectual property, transactional, and strategic business matters.
Scientific Advisor
Victor Vinci, Ph.D.
Scientific advisor bringing 35+ years of experience across Merck, Lilly, Cook Pharmica, and
Catalent, with deep expertise in biologics development to guide GokyoBio's growth.
Scientific Advisor
Scott Estes, Ph.D.
Cell line and cell culture expert bringing 25+ years of experience across Genzyme, Sanofi,
Biogen, Codiak Biosciences, and most recently as head of cell line development at Asimov.
Contact
Get in touch.
For partnership, investor, career, or strategic inquiries, contact GokyoBio directly.